Background: Chronic idiopathic urticaria (CIU) is a debilitating skin disease that affects patients' quality of life (QOL). The Dermatology Life Quality Index (DLQI) assesses QOL parameters across several types of dermatologic conditions. However, an evaluation of the validity of the DLQI for use in CIU patients has not been undertaken, because CIU, unlike other chronic skin conditions, is subject to daily or weekly symptom fluctuations.
Objective: To test the reliability and validity of the DLQI in 2 samples of CIU patients treated with fexofenadine hydrochloride (20, 60, 120, or 240 mg twice daily).
Methods: Data were obtained from 2 similar multicenter, double-blind, randomized, placebo-controlled, parallel-group studies of CIU patients (n = 418 and n = 439). Patients completed the 10-item DLQI during 3 clinic visits (approximately 2 weeks apart). Clinic personnel also recorded patients' symptoms.
Results: The results of the DLQI items were similar to those obtained with other skin disease populations, indicating the presence of relatively symmetrical distributions. Reliability was high, demonstrating the lack of excessive random measurement error (alpha coefficient = .89 and .87 for samples 1 and 2). Factor analysis resulted in a unidimensional pattern, supporting the use of a total DLQI score. Most DLQI items distinguished patients with varying degrees of QOL impairment, highlighting the sensitivity of this instrument. Construct validity was moderate, providing evidence that the DLQI was responsive to changes in patients' clinical status.
Conclusions: The DLQI is a valid, reliable, and clinically useful outcome measure for assessing QOL in CIU patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1081-1206(10)61466-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prevelance of food allergy in patients with chronic idiopathic urticaria: a systematic review and meta-analysis.
Arch Dermatol Res
December 2024
Taibah University, Madinah, Saudi Arabia.
Chronic idiopathic urticaria (CIU) is difficult for patients and healthcare professionals to manage owing to its chronic and unpredictable nature. While the exact cause of CIU is unknown, it is suggested that food allergies may contribute to the development of symptoms. To determine the prevalence of food allergy in patients diagnosed with CIU.
View Article and Find Full Text PDFTurkish nurses' knowledge, attitudes and practices in the management of incontinence associated dermatitis: A descriptive and cross-sectional study.
J Tissue Viability
December 2024
Department of Nursing, Cyprus International University School of Health Sciences, Nicosia, Cyprus. Electronic address:
Objective: This study aimed to determine nurses' current knowledge, attitudes, and practices in adult intensive care units and palliative care clinics regarding incontinence-associated dermatitis (IAD).
Materials And Methods: This descriptive cross-sectional study was conducted with 355 nurses in adult intensive care and palliative services at two hospitals. Data were collected between 5.
A measles virus collective infectious unit that caused lethal human brain disease includes many locally restricted and few widespread copy-back defective genomes.
J Virol
November 2024
Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
During virus replication in cultured cells, copy-back defective viral genomes (cbDVGs) can arise. CbDVGs are powerful inducers of innate immune responses , but their occurrence and impact on natural infections of human hosts remain poorly defined. We asked whether cbDVGs were generated in the brain of a patient who succumbed to subacute sclerosing panencephalitis (SSPE) about 20 years after acute measles virus (MeV) infection.
View Article and Find Full Text PDFTime-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria.
Eur J Clin Pharmacol
October 2024
School of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Guilin, 541004, China.
Article Synopsis
- The study aimed to quantitatively analyze the effects of different doses of omalizumab on patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) and compare it with ligelizumab.
- A model-based meta-analysis was conducted using various literature sources to evaluate the treatment’s efficacy, measured by the Urticaria Activity Score (CFB-UAS7), over time and by dose.
- Results indicated that omalizumab had a significant dose-dependent effect, with ligelizumab potentially outperforming omalizumab at lower doses, particularly at 72 mg and 120 mg.
Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.
Skin Res Technol
May 2024
Department of Dermatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Background: Omalizumab is the only licensed drug that serves as a third-line treatment for chronic idiopathic urticaria (CIU). The optimum doses of omalizumab remain controversial. Therefore, this study aims to estimate the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!